Seeking Alpha

Margaret Dudley

Margaret Dudley
Send Message
View as an RSS Feed
View Margaret Dudley's Comments BY TICKER:
Latest  |  Highest rated
  • Gilead discounts Sovaldi 99% for Egypt [View news story]
    Perhaps the internet will become the new 'Dallas Buyers Club'. Just saying...
    Mar 21, 2014. 10:57 PM | Likes Like |Link to Comment
  • The FDA is reviewing data on a certain class of diabetes drugs which it says might lead to precancerous changes in the pancreas. The drugs may include Eli Lilly's (LLY) Tradjenta, Merck's (MRK) Januvia, Novo Nordisk's (NVO) Victoza, and Bristol-Myers Squibb's (BMY) Byetta. Labels on the drugs already warn of increased potential for pancreatitis, which is the inflamation of the pancreas. The precancerous changes are new, and would affect future labeling. [View news story]
    Where is the interferon and ribavirin-free treatment that was developed by Bristol-Myers & Gilead Sciences? Daclatasvir combined with sofosbuvir cured 100% of genotype 1, 2, 3... without TOXIC RIBAVIRIN. We are asking President Obama to urge these two drug companies to move forward at once to make this life-saving combination available. Gilead has had long enough and has not been able to duplicate daclatasvir capabilities with their ledipasvir. Gilead wants to offer their 'wonder drug' with ribavirin/interferon and they will be 'wondering' why people refuse to treat! Ribavirin is toxic and destroys lives! Ribavirin is thought to be carcinogenic. We need other leading and compassionate doctors to stand up against this big pharma giant in the best interest of THEIR PATIENTS... and not THEIR PORTFOLIOS!
    Mar 15, 2013. 01:18 PM | Likes Like |Link to Comment
  • Gilead Sciences: How Long Can The Giddiness Last? [View article]
    Gilead has not disclosed to their investors the monumental success of the drug combination of GILD sofosbuvir combined with BMY daclatasvir. This combination cured 100% of hepatitis C patients with genotypes 1, 2, and 3, and this 100% cure was achieved without ribavirin or interferon. Other companies, such as ABT, are now seeking their own ribavirin-free cocktails because ribavirin has severe, sometimes permanent side effects, and may be carcinogenic. Gilead holds the 'key to the cure' with sofosbuvir but not the cure itself. Gilead's 5885 (an NS5A inhibitor class drug similar to daclatasvir) combined with sofosbuvir (formerly GS-7977) is only effective in the genotype 1 population and still requires the addition of ribavirin. ABT or other drug companies will possibly beat GILD to market with ribavirin-free cocktails, and GILD investors will be left wondering why GILD did not move forward with a 'sure cure' (again 100% in GT 1,2,3) by continuing collaboration with BMY in order to corner the market with the most successful treatment ever developed in the history of HCV. This is possibly what insiders 'know' and why they are selling off.
    Dec 24, 2012. 04:24 AM | Likes Like |Link to Comment
  • Gilead Sciences Leads The Race In Developing A Hepatitis C Pill [View article]
    Gilead Sciences is "walking away" from most effective treatment in the history of HCV. The combination of sofosbuvir and daclatasvir CURED 100% in trials with Bristol-Myers with minimal side effects. And it was done without ribavirin (which has a list of side effects three pages long, some of which can be permanent, and ribavirin may even cause cancer); and the Gilead/Bristol combo worked genotypes 1, 2, 3. This is the most amazing development since the polio vaccine and not unlike if they had found the 'cure for cancer', since left untreated, hepatitis C can develop into liver cancer. Gilead Sciences' Board of Directors as well as their shareholders need to take note of this. Gilead Sciences is "sitting on the cure" instead of rushing to make this life-saving combination available as quickly as possible. Gilead could begin getting returns on their $11 billion investment almost immediately, not to mention saving hundreds of thousands of lives. Gilead Sciences stated back in April that they were waiting to see the results from these trials six months after people completed treatment before deciding if they would move forward with this miraculous drug combination. The results are in and were presented at the last AASLD Liver Meeting two weeks ago...and the results are: 100% cured without ribavirin. (Note: Have holdings in Gilead Sciences)
    Dec 9, 2012. 06:06 AM | 2 Likes Like |Link to Comment
  • New Second Generation Combination Therapy For HCV - First Or Best In The Market (Part 1) [View article]
    Daclatasvir and sofosbuvir biggest development in the history of HCV! The HCV Coalition for The Cure has launched petition at and more than 8300 people have signed expressing their outrage about the lack of further collaboration on this life-saving drug combination. Only therapy that treats genotypes 1a, 1b, 2 & 3 and without ribavirin. Encourage everyone infected or affected by this disease to sign as well. We need someone in the HCV medical arena to step forward on behalf of HCV sufferers everywhere!
    Nov 19, 2012. 09:38 AM | Likes Like |Link to Comment
  • Bristol-Myers Squibb (BMY) says it's stopped development of an experimental hepatitis C treatment connected to the hospitalization of nine patients and the death of one. The drug, known as BMS-986094, had been used in a mid-stage clinical study, which BMY recently suspended. The cause of the adverse events, while not "definitively established," involved heart and kidney toxicity, the drug maker said. [View news story]
    BMY's daclatasvir (formerly BMS-790052) combined with GILD's GS-7977 CURED 100% of genotype 1 and 91% of genotype 2/3 w/o interferon or ribavirin in phase II trials. This development was stopped by GILD and millions with HCV are now left to continue suffering and dying when what appears to be the best development in the history of HCV has been found. This is what all the news should be about!
    Aug 24, 2012. 01:10 AM | Likes Like |Link to Comment